The principal activity of the group is developing a practical system for monitoring blood flow perfusion (oxygen transport) and important heart dynamics. It is noninvasive, continuous, and uses a simple comfortable disposable sensor. This addresses key issues of hospital critical care. The Company's FDA-cleared CNBP system was recently cost re-engineered to be the first price competitive continuous system for upgrading a market of over a million units. The company recently enhanced this technology to include a single-patient use sensor for an optional CNBP "platform" for upgrading users to blood flow perfusion monitoring without the delay of capital budgeting. The company serves the health care industry.
